Medicare Enrolled
Dr. Gregory Mauldin, MD
Pulmonary Disease · Snellville, GA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Mauldin from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mauldin?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Mauldin
Dr. Gregory Mauldin is a pulmonary disease specialist in Snellville, GA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Mauldin performed 1,125 Medicare services across 797 unique beneficiaries.
Between the years covered by Open Payments, Dr. Mauldin received a total of $302,067 from 52 pharmaceutical and/or device companies across 1068 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Mauldin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 40% volume in GA
$302,067 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,125
Medicare services
Top 40% in GA for pulmonary disease
797
Unique beneficiaries
$81
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~59 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
281 | $90 | $367 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
189 | $94 | $328 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
86 | $10 | $50 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
64 | $62 | $200 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
63 | $113 | $492 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
52 | $42 | $161 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
51 | $30 | $125 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
51 | $42 | $156 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
49 | $70 | $179 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
45 | $27 | $100 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
45 | $136 | $526 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
38 | $131 | $511 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
25 | $168 | $673 |
| Pneumococcal conjugate vaccine (PCV20) An intramuscular injection of the 20-valent pneumococcal conjugate vaccine. It is used to protect against diseases caused by Streptococcus pneumoniae bacteria. |
20 | $281 | $1,387 |
| Pneumonia vaccine administration This procedure involves the injection of a vaccine to protect against pneumococcal disease. It is administered by a healthcare provider. |
20 | $29 | $30 |
| New patient office visit, complex (60-74 min) | 18 | $171 | $608 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
14 | $71 | $212 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
14 | $30 | $40 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$302,067
Total received (2018-2024)
Avg $43,152/year across 7 years
Top 1% in GA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
52
Companies
1,068
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$286,118 (94.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,512 (4.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,437 (1.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,886
2023
$6,021
2022
$3,870
2021
$5,245
2020
$33,324
2019
$166,307
2018
$84,413
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GENZYME CORPORATION
$1,062
GlaxoSmithKline, LLC.
$266
Regeneron Healthcare Solutions, Inc.
$212
Actelion Pharmaceuticals US, Inc.
$175
ABBVIE INC.
$169
Grifols USA, LLC
$139
Amgen Inc.
$132
Mylan Specialty L.P.
$105
AstraZeneca Pharmaceuticals LP
$91
Boehringer Ingelheim Pharmaceuticals, Inc.
$91
Takeda Pharmaceuticals U.S.A., Inc.
$73
Inspire Medical Systems, Inc.
$67
Resmed Corp
$45
HARMONY BIOSCIENCES LLC
$45
Vifor Pharma, Inc.
$43
United Therapeutics Corporation
$26
Insmed, Inc.
$26
CSL Behring
$25
Baxter Healthcare
$23
Paratek Pharmaceuticals, Inc.
$22
Phadia US Inc.
$21
Tactile Systems Technology Inc
$14
Axsome Therapeutics, Inc.
$13
Top 3 companies account for 53.3% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$86,146
AstraZeneca Pharmaceuticals LP
$83,031
Mylan Specialty L.P.
$48,929
Regeneron Healthcare Solutions, Inc.
$28,480
Janssen Pharmaceuticals, Inc
$26,866
Sunovion Pharmaceuticals Inc.
$9,998
Boehringer Ingelheim Pharmaceuticals, Inc.
$8,648
GENZYME CORPORATION
$3,936
Olympus Corporation of the Americas
$979
Actelion Pharmaceuticals US, Inc.
$623
ViiV Healthcare Company
$600
Amgen Inc.
$529
Grifols USA, LLC
$419
Takeda Pharmaceuticals U.S.A., Inc.
$282
ABBVIE INC.
$260
United Therapeutics Corporation
$239
PFIZER INC.
$206
Mallinckrodt Hospital Products Inc.
$159
Allergan, Inc.
$158
Galderma Laboratories, L.P.
$155
Harmony Biosciences LLC
$148
Novartis Pharmaceuticals Corporation
$121
Inspire Medical Systems, Inc.
$103
Genentech USA, Inc.
$102
HARMONY BIOSCIENCES LLC
$81
Resmed Corp
$76
Insmed, Inc.
$69
Baxter Healthcare
$59
Intuitive Surgical, Inc.
$50
Circassia Pharmaceuticals Inc
$50
Mallinckrodt Enterprises LLC
$47
Shire North American Group Inc
$44
Vifor Pharma, Inc.
$43
Advanced Respiratory, Inc
$40
PORTOLA PHARMACEUTICALS, INC.
$35
JAZZ PHARMACEUTICALS INC.
$29
Gilead Sciences, Inc.
$28
SANOFI-AVENTIS U.S. LLC
$28
ADVANCED RESPIRATORY, INC
$27
Johnson & Johnson Health Care Systems Inc.
$27
Allergan Inc.
$26
CSL Behring
$25
Paratek Pharmaceuticals, Inc.
$22
Phadia US Inc.
$21
La Jolla Pharmaceutical Company
$19
Teva Pharmaceuticals USA, Inc.
$18
Mallinckrodt LLC
$17
Veran Medical Technologies, Inc.
$17
Merck Sharp & Dohme Corporation
$15
Tactile Systems Technology Inc
$14
Axsome Therapeutics, Inc.
$13
Itamar Medical Inc
$11
Top 3 companies account for 72.2% of all-time payments
Associated products mentioned in payments ›
120V · 60Hz · ACTHAR · AIRSENSE · AIRSUPRA · ANDEXXA · ANORO · ANORO ELLIPTA · AREXVY · AVYCAZ · AirFit · Arikayce · BEVESPI AEROSPHERE · BEVYXXA · BOTOX · BOTOX COSMETIC · BREO · BREZTRI · BROVANA · CHANTIX · CINQAIR · DALIRESP · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · Da Vinci Surgical System · Dymista · ELIQUIS · Esbriet · FARXIGA · FASENRA · Flexitouch Plus · GIAPREZA · GLASSIA · Hillrom - Life 2000 Ventilation System · Hillrom - Vest System Model 105 Home Care · Hizentra · INSPIRE · ImmunoCAP · LONHALA MAGNAIR · NIOX VERO · NO PRODUCT DISCUSSED · NUCALA · NUZYRA · OFEV · OPSUMIT · ORENITRAM · Otezla · Prolastin-C Liquid · Repatha · SINGLE USE SUCTION VALVE (Sterile) · SPIRIVA RESPIMAT · SPiN Thoracic Navigation System · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · Single Use Guide Sheath Kit · Sunosi · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The Vest System Model 105 Home Care · UPTRAVI · UTIBRON · Utibron · WAKIX · Wakix · WatchPAT · XARELTO · XOLAIR · Xembify · Xolair · YUPELRI · Yupelri · Zemaira · myAir
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (95%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in pulmonary disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for pulmonary disease in GA.
Geographic Context
Pulmonary diseases within 10 mi
110
Per 100K population
11.4
County median income
$84,823
Nearest hospital
PIEDMONT EASTSIDE MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Mauldin is a clinical cardiology specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 1% of GA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Mauldin experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Mauldin performed 281 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mauldin receive payments from pharmaceutical companies?
Yes. Dr. Mauldin received a total of $302,067 from 52 companies across 1,068 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mauldin's costs compare to other pulmonary diseases in Snellville?
Dr. Mauldin's average Medicare payment per service is $81. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mauldin) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Snellville
Browse pulmonary diseases in Snellville ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in GA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in GA
Which GA pulmonary diseases receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Mylan Specialty L.P. Payments to Doctors
See all physicians who received payments from Mylan Specialty L.P.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology